logo-loader
viewSynairgen PLC

Synairgen chief thrilled with AstraZeneca deal

Synairgen (LON:SNG) chief executive Richard Marsden says the licensing deal with drugmaking giant AstraZeneca for its breakthrough asthma treatment is proof that the business model works.

The boss of the AIM-listed drug discovery group explains that Astra do all the work on SNG001 from here, which will give Synairgen the chance to boost its drug pipeline and hopefully repeat the trick in future.

Quick facts: Synairgen PLC

Price: 35 GBX

AIM:SNG
Market: AIM
Market Cap: £52.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read